Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/ARID2_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/ARID2_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/ARID2_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/ARID2_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/ARID2_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/ARID2_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/ARID2_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/ARID2_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/ARID2_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004001314 | Oral cavity | NEOLP | negative regulation of locomotion | 69/2005 | 391/18723 | 2.05e-05 | 3.41e-04 | 69 |
GO:003105631 | Oral cavity | NEOLP | regulation of histone modification | 34/2005 | 152/18723 | 2.31e-05 | 3.72e-04 | 34 |
GO:003298431 | Oral cavity | NEOLP | protein-containing complex disassembly | 45/2005 | 224/18723 | 2.33e-05 | 3.72e-04 | 45 |
GO:00030074 | Oral cavity | NEOLP | heart morphogenesis | 48/2005 | 246/18723 | 2.80e-05 | 4.32e-04 | 48 |
GO:199083021 | Oral cavity | NEOLP | cellular response to leukemia inhibitory factor | 24/2005 | 94/18723 | 3.85e-05 | 5.57e-04 | 24 |
GO:000632521 | Oral cavity | NEOLP | chromatin organization | 70/2005 | 409/18723 | 4.97e-05 | 6.83e-04 | 70 |
GO:005105231 | Oral cavity | NEOLP | regulation of DNA metabolic process | 63/2005 | 359/18723 | 5.48e-05 | 7.44e-04 | 63 |
GO:200102031 | Oral cavity | NEOLP | regulation of response to DNA damage stimulus | 43/2005 | 219/18723 | 6.13e-05 | 8.19e-04 | 43 |
GO:005105431 | Oral cavity | NEOLP | positive regulation of DNA metabolic process | 40/2005 | 201/18723 | 8.01e-05 | 1.01e-03 | 40 |
GO:000647922 | Oral cavity | NEOLP | protein methylation | 37/2005 | 181/18723 | 8.15e-05 | 1.02e-03 | 37 |
GO:000821322 | Oral cavity | NEOLP | protein alkylation | 37/2005 | 181/18723 | 8.15e-05 | 1.02e-03 | 37 |
GO:00485686 | Oral cavity | NEOLP | embryonic organ development | 71/2005 | 427/18723 | 1.12e-04 | 1.34e-03 | 71 |
GO:001820531 | Oral cavity | NEOLP | peptidyl-lysine modification | 64/2005 | 376/18723 | 1.21e-04 | 1.43e-03 | 64 |
GO:004592621 | Oral cavity | NEOLP | negative regulation of growth | 46/2005 | 249/18723 | 1.58e-04 | 1.77e-03 | 46 |
GO:004853821 | Oral cavity | NEOLP | thymus development | 14/2005 | 45/18723 | 1.67e-04 | 1.86e-03 | 14 |
GO:001657122 | Oral cavity | NEOLP | histone methylation | 30/2005 | 141/18723 | 1.77e-04 | 1.95e-03 | 30 |
GO:0060840 | Oral cavity | NEOLP | artery development | 23/2005 | 100/18723 | 3.00e-04 | 2.97e-03 | 23 |
GO:003496822 | Oral cavity | NEOLP | histone lysine methylation | 25/2005 | 115/18723 | 4.21e-04 | 3.89e-03 | 25 |
GO:004886316 | Oral cavity | NEOLP | stem cell differentiation | 38/2005 | 206/18723 | 5.82e-04 | 5.05e-03 | 38 |
GO:0048844 | Oral cavity | NEOLP | artery morphogenesis | 18/2005 | 74/18723 | 6.49e-04 | 5.47e-03 | 18 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ARID2 | SNV | Missense_Mutation | | c.3931N>G | p.Lys1311Glu | p.K1311E | Q68CP9 | protein_coding | tolerated_low_confidence(0.06) | benign(0.444) | TCGA-A7-A13E-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Targeted Molecular therapy | bevacizumab | PD |
ARID2 | SNV | Missense_Mutation | | c.4304C>T | p.Ser1435Leu | p.S1435L | Q68CP9 | protein_coding | tolerated_low_confidence(0.14) | benign(0) | TCGA-A8-A06T-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | anastrozole | SD |
ARID2 | SNV | Missense_Mutation | | c.1113N>C | p.Lys371Asn | p.K371N | Q68CP9 | protein_coding | tolerated(0.08) | probably_damaging(0.991) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
ARID2 | SNV | Missense_Mutation | novel | c.3877N>A | p.Leu1293Ile | p.L1293I | Q68CP9 | protein_coding | tolerated_low_confidence(0.08) | benign(0.019) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ARID2 | SNV | Missense_Mutation | | c.5199T>G | p.Ile1733Met | p.I1733M | Q68CP9 | protein_coding | deleterious(0.01) | benign(0.294) | TCGA-AN-A0FW-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
ARID2 | SNV | Missense_Mutation | | c.4364N>A | p.Ser1455Asn | p.S1455N | Q68CP9 | protein_coding | tolerated(0.08) | benign(0) | TCGA-AO-A0JD-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | SD |
ARID2 | SNV | Missense_Mutation | | c.1715N>A | p.Arg572Lys | p.R572K | Q68CP9 | protein_coding | tolerated(0.1) | probably_damaging(0.987) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
ARID2 | SNV | Missense_Mutation | | c.4531N>A | p.Glu1511Lys | p.E1511K | Q68CP9 | protein_coding | deleterious_low_confidence(0) | benign(0.257) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
ARID2 | SNV | Missense_Mutation | | c.2713C>A | p.Gln905Lys | p.Q905K | Q68CP9 | protein_coding | tolerated_low_confidence(0.38) | benign(0.01) | TCGA-BH-A18N-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ARID2 | SNV | Missense_Mutation | novel | c.4758N>T | p.Gln1586His | p.Q1586H | Q68CP9 | protein_coding | deleterious(0.02) | possibly_damaging(0.564) | TCGA-BH-A2L8-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | CR |